» Articles » PMID: 9345359

Carcinosarcoma of the Uterus: a Clinicopathological Multicenter CTF Study

Overview
Journal Gynecol Oncol
Date 1997 Nov 5
PMID 9345359
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this paper is to retrospectively analyze the clinical and pathological data of 118 cases of uterine carcinosarcoma. Prognostic factors and management were evaluated. chi 2 and log-rank tests were performed. Surgical stage at time of surgery was the most important prognostic factor (P < 0.0001); in stage I-II disease depth of myometrial invasion and lymphatic/vascular space involvement were significantly related to outcome, whereas other factors were not useful. In stage I-II patients postoperative radiation did not improve 5-year disease-free survival. Survival curves in patients with advanced disease treated with cisplatin-containing regimens or with doxorubicin (without cisplatin)-containing regimens were overlapping.

Citing Articles

Clinical and multiparametric MRI features for differentiating uterine carcinosarcoma from endometrioid adenocarcinoma.

Chen X, Guo Q, Chen X, Zheng W, Kang Y, Cao D BMC Med Imaging. 2024; 24(1):48.

PMID: 38373912 PMC: 10877902. DOI: 10.1186/s12880-024-01225-4.


Is the sarcomatous component (homologous vs heterologous) the prognostic "driving force" in early-stage uterine carcinosarcomas? A retrospective multicenter study.

Rosati A, Vargiu V, Certelli C, Arcieri M, Vizza E, Legge F J Cancer Res Clin Oncol. 2023; 149(9):6479-6488.

PMID: 36773091 PMC: 10356890. DOI: 10.1007/s00432-023-04594-5.


Uterine carcinosarcoma: A 10-year single institution experience.

Terblanche L, Botha M PLoS One. 2022; 17(7):e0271526.

PMID: 35862371 PMC: 9302809. DOI: 10.1371/journal.pone.0271526.


Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network.

Romeo C, Le Saux O, Jacobs M, Joly F, Ferron G, Favier L Cancers (Basel). 2022; 14(2).

PMID: 35053517 PMC: 8773830. DOI: 10.3390/cancers14020354.


Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.

Powell M, Filiaci V, Hensley M, Huang H, Moore K, Tewari K J Clin Oncol. 2022; 40(9):968-977.

PMID: 35007153 PMC: 8937015. DOI: 10.1200/JCO.21.02050.